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Abstract
This paper analyzes the strategic alliances in the emerging bio-phar-
rna industry in Asia as bio-pharma companies pursue multiple sources of
competitive advantage in an industry that has become more global and
where competition· has become more fierce and pressure for cost, time
and innovation is high. How these firms form alliances that bring
together complementary competences and assets, facilitate entry into a
foreign market and increase market presence, and spread and reduce
costs of innovation in order to survive in the domestic and international
market will likewise be presented.
Keywords: Firm strategy, strategic alliances, bio-pharma, biotechnol-
ogy, Asia
Introduction
Biotechnology is now revolutionizing the health care industry as more phar-
maceutical companies are deriving novel products from the biotech sector.
Moreover, the emergence of bioinformatics and bioservices have brought
medical diagnosis and delivery to a higher level. In Asia, biotech companies
are trying to thrive in niche markets in drug screening and manufacturing,
bioinformatics and genomics (Economist b, 2004). Therapeutics for the
treatment of diseases common in Asia such as respiratory and infectious dis-
70 KEIEI TO KEIZAI
ease, and cardiovascular ailments are the focus of many biotech firms in
Asia. India, for example, manufactures vaccines, therapeutics, and diagnos-
tics most of which are to meet the domestic health needs (such as hepatitis
B, typhoid, diabetes, cancer, cardiovascular, malaria, cholera, encephalitis,
HIV) of the 1 Billion population.. Although China is intensifying its efforts in
genomics and stem cells, biotech companies have also developed biomedical
products for the treatment of hepatitis Band C, SARS, cancer, anemia, and
cardiovascular ailments, the more common diseases in the country (Zhen-
zhen et.al., 2004). Against this background, this chapter will study how
pharmaceutical companies in the region are pursuing multiple sources of
competitive advantage in an industry that has become more global and
where competition has become more fierce and pressure for cost, time and
novel drugs are high.
Fledgling Biotech Industry in Asia
The biotech industry in Asia as compared to that in the US and Europe is
still in the emerging stage and relatively small in terms of size, revenues and
expenditures on research. But governments of some Asian countries like
Japan, Singapore, South Korea, India and China expect that the biotech sec-
tor would be the next engine of growth of their economies.
Table 1. Performance of the Biotech Industry, 2004.
Regions No. of Cos.




US 1,444 28 US$42,740 US$15,701 137,000
Europe 1,815 8 7,729 4,151 25,640
Asia-Pacific 685 17 2,052 253 13,410
Source: Ernest & Young, Beyond Borders: Global Biotechnology Report 2005.
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The sector, however, has performed remarkably well in Asia in 2002-2003,
better than in Europe where negative growth rates have been registered in
terms of number of companies, revenues and R&D expenditures. The 11%
increase in the number of companies is an indication of the fast pace of
growth of the biotech sector. Similarly the substantial surge in investments
in research and development reflects the drive in Asia to innovate which is
the lifeline of companies in the industry (Table 2). Evidently, the industry
is growing in the Asia Pacific. and many see the region as the next biotech
hub.
Table 2. Percentage Growth of Global Biotech Sector, 2002-2003.
Region Revenues No. of companies
R&D
Expenditures
Asia 9.0% 11.0% 10.0%
US 22.5% 0.1% -13.3%
Europe -12.0% -1.0% -17.0%
Source: Louet, Sabine (2004) E&Y Report Backs Asia Pacific Biotech,
Nature Biotechnology, Vol. 22 No.7.
In the early 1980s, Japanese big companies but non-pharmaceuticals compa-
nies in Japan for that matter had been involved in biotech research in col-
laboration with foreign companies. In spite of this, however the biotech sec-
tor did not grow as expected. For example Mitsubishi Kasei (which merged
with Mitsubishi PetroChemical Corporation to form the Mitsubishi Chemical
Corporation in 1994) was already engaged in biotechnology research and in
1982 allied with Genentech. Under license from Genentech, Mitsubishi
Chemical brought into the market two rDNA drugs: tissue plasminogen ac-
tivator for coronary thrombosis and hepatitis-B vaccine. Likewise they have
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collaborated with IDEC, a US biotech company for the development of ther-
apeutic monoclonal antibodies for auto-immunity and transplant rejection
(Heissler, 1995). Kirin Brewery, the largest beer company in Japan, estab-
lished in 1982 a drug division and did research on anti-cancer, cardiovascular
and immuno/allergic medications. At that time Kirin launched its first gene
recombinant drug erythropoietin (EPO) , sold as Espo (EPO) , used to
treat anemia of patients undergoing' analysis with technology from US Am-
gen. Kirin and Amgen also co-developed G-CSF (granulocyte colony
stimulating factor), commercialized as Gran. G-CSF promotes the produc-
tion of white blood cells and is used to treat cancer patients that are suffer-
ing from leucopenia caused by chemotherapy and bone marrow transplants.
Kirin successfully marketed EPO and G-CSF in Japan as well as in Taiwan
and South Korea in the early 1990s. The small homegrown dedicated biotech
firms (DBFs) in Japan however such as AnGes MG, Trans Genic, Medinet
and Onco Therapy Science have to work on their own with their limited capi-
tal since unlike in the US and Europe, the big Japanese pharmaceutical com-
panies would rather do R&D by themselves than form alliances with oar ac-
quire small local biotech companies China on the other hand has strong tradi-
tional indigenous and herbal based, products and the biotech sector specially
biopharma industry started to emerge in the 1980s.. Until the mid-1980s,
most of the drug companies in China were publicly funded, state-owned or
spin-offs of public research institutions that produced imitation drugs (Jia-
he, 2002). In China, the best high standard researches are done by scien-
tists in public laboratories and universities which hold 80 % of the patents of
therapeutics and vaccines (Zhenzhen, et. aL 2004). Venture capital in
China is lacking and this then limits venture creation and retrains the con-
version' of public research institutions and their R&D results into
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entrepreneurial business activities.
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Although biotechnology in Asia started decades ago, it has remained lagging
vis a vis their Western counterparts. Most R&D in biotech in Asia are done
in public laboratories and national universities that are staffed by world class
scientists that have access to world class research facilities and infrastruc-
tures and these institutions often owned the patents. However, there were
no sufficient incentives to commercialize biotechnology output not to men-
tion the lack of a structure to connect academic research with business
hence limiting the transfer of technology to the industrial sector. Moreover
due to the lack of entrepreneurial spirit and venture capital, start ups were
minimal. Few bioventure spin-offs from universities and public research in-
stitutions existed. Venture capitalist shied away from the more risky biotech
sector since the rate of R&D results successfully reaching the commerciali-
zation stage after huge R&D and clinical trials costs is comparatively low
compared to other industries. But recently with bioventure funds established
by the Japanese government, there has been an increase in spin-off compa-
nies that are nurtured in the government-run biocenters and finally offered
as IPOs. From 2002-2004, there were 11 biotech IPOs in Japan two years af-
ter the government allowed university professors to join the biotech indus-
try. As of 2005, there were 387 biotech startups half of which are in medical
R&D, not to mention the 300 already established biotech firms. The Chinese
government meanwhile cognizant of the undeveloped venture capital market
in the country wants to develop home grown biotech firms through more
state and local governments financing quasi-venture capital companies, pri-
vate sector investments as well as investments by multinational biotech
firms in the country with cost as the main investment incentive.
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Government Initiatives in Biotechnology
In many Asian nations, the government's role to develop the biotech sector
comes in many forms. For one, the South Korean government has invested
around US$4. 4 B from 2000-2007 into the biotechnology sector. Funding
goes to the country's best universities and public laboratories to do adult and
embryonic stem cell research whereas the Ministry of Commerce, Industry
and Energy subsidizes and provides fiscal incentives to the private sector to
indulge in the applications of biotechnology R&D output. One good example
is Macrogen which is a spin-off business venture of a Seoul National Univer-
sity laboratory in 1997. The company designs DNA sequencing and is map-
ping the "Korean" genome structure. It has mapped 100,000 bacterial ar-
tificial chromosomes of Koreans containing the whole genome of a Korean
person which it utilizes to develop DNA genome arrays (Wong, et.al.,
2004).
In Asia, public research institutions, laboratories and universities are known
for their leading roles in R&D in biotech usually in line with the gover-
nment's overarching goal of safeguarding the basic needs and health of the
local people. Some of the research centers are arms of the government
ministries and some small biotech companies are spin offs from these public
and university laboratories. The main purpose of the collaboration between
the public institutions and the biotech companies is to find solution to dis-
eases prevalent in the country/region'. An example of this public-private alli-
ance is the Novartis Institute for Tropical Diseases (NTD) situated in Singa-
pore which Novartis is pursuing in partnership with the Singapore Economic
Development Board with a US$122M budget to discover medicines for the
treatment of tropical diseases like malaria, dengue and tuberculosis. Medion
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Pharma, Singapore's first homegrown enterprise, was founded in 2002 with
the privatization of the Center for Natural Product Research (CNPR) in par-
tnership with Fujisawa Pharmaceutical Co. Ltd (Japan), John Hopkins Pte.
Ltd (Singapore) and the ,National Cancer Center to discover and develop
new therapeutic drugs from natural sources. Merlion boasts of the following
assets and capabilities of CNPR which it is capitalizing on : advanced drug
discovery techniques, efficient screening of natural product samples in
search of various new bioactive compounds, and the biggest and most
diverse collection of natural product samples in the world. (Biomed, 2002).
In China meanwhile, Novartis recently formed a partnership in 2004 with the
national Shanghai Institute for Materia Medica which has the expertise to
identify compounds derived from traditional Chinese medicine that Novartis
may be able to develop into new drugs. (Santini. 2004). SINOVAC
Biotech Ltd. of China is also actively engaged in the research and develop-
ment of vaccines for the Avian flu which is a recent phenomenon in Asia
together with the Center for Disease Control of China (Business Wire,
2005).
Genomics and Stem Cell Research
Genomics and stem cell research are areas where Asia, with its heterogene-
ous gene resources is trying to find a niche market. The stem cells can be
directed to form different kinds of specialized cells from which organs can be
created and used in therapeutic cloning which means replacing cells des-
troyed due to Parkinsons and type 1 diabetes (Economist a, 2004) or even
to generate replacement tissues or organs lost due to some ailments
(Economist c, 2005). These cells have the healing potentials by forming
cells which replace cells that do not function due to disease or accident
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(Stem Cell Research Foundation, 2005). For stem-cell researchers, Singa-
pore offers one of the world's most liberal legal environment. The law per-
mits stem cells to be taken from aborted fetuses, .and human embryos to be
cloned and kept for up to 14 days to produce stem cells. This is one field the
Biomedical Research Council (BMRC)wants the city state to have a niche
market. The government thus provided US$600 M to fund startups in stem
cell and life science researches, US$22M of which has been put intoES Cell
International. Its chief scientist is the world famous English scientist, Alan
Colman. Stem cell research in Singapore was pioneered by Prof. Ariff Bon-
gso who was the first to successfully isolate stem cells from a five day old
embryo in 1994. Eight years later, again he was the first to culture human
embryonic stem cell lines without the assistance of mouse feeder cells (In-
ternational Stem Cell Forum, 2005). ES Cell International is a spin-off of
this work of Bongso. The company now owns 6 of the human embryonic cell
lines that are supplied worldwide. The use of stem cells as cure for diabetes
is the current research focus of ES Cell International. According to the Stem
Cell Research Foundation, embryos are the source of the most versatile
stems cells. Due to ethical consideration, research has been directed on cord
blood as the source of stem cells. In this regard, Cell Research Corporation
in Singapore has successfully differentiated the outer amniotic lining of the
umbilical cord into specific cells such as skin bone and fat. Stem cell
research results are now being tested for their applicability in Singapore.
Leukemia patients at the Singapore General Hospital are being treated with
haematopoietic stems cells taken from the umbilical cord blood CInternation-
alStem Cell Forum, 2005). Cognizant of the market potentials of the stem
cell research results, CyGenics was established in 2004 in Singapore CShan~
ley" 2005). The company markets adult stem cell related products, serv-
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ices and technology with the assurance that they will make the technology
safe for human use. The company has a blood bank that stores the frozen
umbilical cord blood for possible use for lymphoma, anemia and bone mar-
row cancer (Shanley, 2005).
After the series of political and economic reforms in China, the country has
started to develop its health biotech industry only in the 1980s. One sector
where China is making a mark globally is in the area of genomics. It is the
only developing country to join the Human Genome Project and thereby
paved the way to the establishment of the Beijing Genomics Institute and the
Chinese National Genome Center. In no time was 1% of the human genome
sequenced with a 99% accuracy (Zhenzhen, et.al., 2004). The country is
also gaining headway in gene therapy. At a cost of US$9. 6 M, Shenzhen
Sibono GenTech was able to develop Gendicine, a recombinant ad-p53 gene
therapy type for the treatment of head and neck cell carcinoma. Moreover,
Chinese researchers were the first to research on adult stem cells from blood
and umbilical cord. One advantage China has is its many homogenous sub-
populations which are important for clinical trials and good for functional
genomics and disease gene identification (Zhenzhen, et.al., 2004).
Interindustry convergence: Bioinformatics and Nanomedicine
Various high tech industries are converging and intersecting and have
diverse applications (Barlett and GhoshaL 2002). The technology and skill
demands of many high tech firms at the present time go beyond the firm's
capability. The better option they pursue amid the fast changing demands of
the times and global business environment is to collaborate and exchange
technology. Biotechnology has become so advanced that it has become an
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interdisciplinary industry. The convergence of complementary industries is
warranted due to the pressure of time, risk and costs. Bioinformatics is one
case in point. The levels of information technology and expertise in Japan,
Singapore, Korea, Taiwan, and India are very high. These countries have
world class and highly competitive information technology (IT) companies.
This gives them leverage in areas where IT and biotechnology converges,
e.g., bioinformatics which is the interface between experimentation and
computation (BioSino, 2003) specially in the field of gene sequencing and
stem cell research. Wooley of the University of California-San Diego men-
tioned the important role of bioinformatics from now on due to the complex
computations needed in basic research and experimentation as more R&D
results are applied. Japanese IT firms are forming partnerships on their own
with domestic and international biotech firms to combine their complementa-
ry expertise. Hitachi formed a synergy with Yamanouchi Pharmaceuticals in
genomic research. Itochu using its discovery platform for high level protein
research has allied with USProteomics, a. bioinformatics firm (BioSino
2003). Japan's advanced development of nanotechnology could always give
it competitive edge in the application of nanotechnology in pharmaceutical
research. Unlike in Japan where the highly competitive IT firms seek their
partners at home and abroad, in Singapore where the biotechnology sector is
still in its nascent stage, the government leads the initiative to develop bioin-
formatics in the country by creating the Center of Systems Biology and
together with Eli Lilly apply bioinformatics in the study of biological systems
(BioSino, 2003). Japanese companies are now gaining headway in putting
into practical use nanotechnology as a new drug delivery system targeting
cancer cells. This new drug delivery system was developed by NanoCarrier
Co, a biotech start-up and Nippon Kayaku, a chemical and pharmaceutical
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company. Japan is also making a lot of progress in nanotechnology and its
functionality in terms of nanomedicine and bio-imaging. A group of resear-
chers from Kyoto University, Terumo Corporation and Nippon Shinyaku Co.
are developing a technology to treat malignant tumors by injecting patients
with peptides (an amino acid compound) that have light emitting particles
for identification, and cancer cell killing therapy for cure, attached to it.
(Kato, K., 2005) .
Firm strategy in Alliance Formation
Firms form strategic alliances to achieve the following objectives: bring
together complementary competences and assets which each of the company
lacks ; facilitate entry into a foreign market and increase market presence ;
and spread and reduce costs and risks in the costly development of new
drugs. In the next section, case studies of how biotechnology companies in
Asia build strategic alliances to fulfill these objectives will be presented.
Economies of Scale and Scope
Strategic alliance also refers to the cooperative agreement between actual
competitors and companies in the same line of business. Companies resort to
this strategy to have more market power and new economies of scale and
scope which are very evident in the Japanese pharmaceutical sector. Japan is
the second biggest drug market in the world worth US$58B hence is an at-
tractive market for the big and well-established pharmaceutical companies in
the West such as Pfizer, Novartis-Pharma KK and AstraZeneca. In Japan
survival of the pharmaceutical sector depends on its financial strength and
global reach which most Japanese firms lack. During the time when the
Japanese market was protected from multinational drug makers, domestic
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pharmaceutical firms relied on the domestic market and enjoyed high
profitability mostly from licensing deals with foreign companies. In 2003,
Datamonitor reported sales from drugs that have been developed a decade
ago and many whose patents will expire (referred to as long-listed drugs)
and are subject to price reductions are the main sources of revenues of 60%
of drug companies in Japan (Mayer,' ·2005). With sales growth remaining
stagnant or declining for these mature and disappearing pipelines, compa-
nies then had to resort to in-licensing. With not much capital to develop new
drugs but with the core competence in the invention of new chemical com-
pound Kyorin is linking up with multinational drug makers to develop
"global scale medicines" (Kato. T., 2005) and uses the partner's global
distribution channels. Kyorin in effect is an example ofa royalty income
pharmaceutical company (RIPCO) that licensed out its Norfloxacin and
Gantifloxacin to large American pharmaceutical companies, Merck and Co.
and Bristol-Myers Squibb, respectively, both for pioneering new quinolone
antibacterial agents. The Japanese pharmaceutical market has been tradi-
tionally closed to foreign drug manufacturers, and Japanese companies have
gotten a big percentage of their incomes from producing in-licensed drugs
and not from novel drugs. As of 2004, Takeda has been the licensee for the
following drugs: in 2004, Sucampo Pharmaceuticals In.c., for constipation;
in 2004, BioNumerik Pharmaceuticals for preventing neuropathy caused by
chemotherapy; in 2001, Andrx for diabetes, in 2003, Eli Lilly for diabetes,
in 2002, Ajinomoto for' osteoporosis; in 2001, Mitsubishi Pharma for dia-
betic neuropathy; and in 2001, Dainippon Pharmaceuticals for gastro-
esophageal reflux disease (Takeda Chemicals, 2005).
Recently, the Japanese government has been cutting drug prices and non-
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Japanese pharmaceutical companies Can easily get drug approvals. With the
aging population in Japan, the government under the national insurance sys-
tem would like to scale down the increasing medical expenses, hence drug
prices are being reduced almost every 2 years. This will have bigger reper-
cussions on the revenues of small and medium sized pharmaceutical compa-
nies such as Tanabe, and Shionogi since 92% and 90% of their sales, respec-
tively, are from the domestic market unlike the big pharmaceutical compa-
nies like Takeda and Astellas that derive 40-50% of their sales from over-
seas markets. The recent revisions in the Pharmaceutical Affairs Law which
took effect on AprilL 2005 made it easier for foreign pharmaceutical com-
panies to do business in Japan with regard to product registration, industry
standards, clinical trials, labeling, advertising, product classification, and in-
tellectual property (Hill, R., 2005). From now on the foreign multinationals
can market the imported drugs themselves and can use contract manufactur-
ing instead of having to build their own manufacturing facilities in Japan.
(Hill, R., 2005). The increasing presence of multinational pharmaceutical
firms in Japan is evident by the rise in the market share they hold from 18%
in 2002 to 27% in 2003. GSK, Pfizer, Novartis and AstraZeneca now market
their products using their own sales forces. These companies are offering
their local rivals in Japan tough competition with the adoption of aggressive
marketing strategies and more importantly the continuous introduction of
novel drugs that these international drug companies have sold successfully
in other overseas markets like the cholesterol lowering drug, Lipitor, than
license their products to Japanese pharmaceutical companies (Kato, T.,
2005). The Japanese drug companies are now faced with two dilemmas: no
new drugs in the pipeline and no resources to have international reach.,
Hence the Japanese companies have to come up with their own innovative
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drugs that require as much as Yen 100 B in R&D costs. The US drug makers
dwarfs the sales and R&D expenditures of Japanese drug companies;
around Yen 800 B is spent on R&D by Pfizer alone. To counter the size of
these big pharmaceutical firms in the US and Europe and the cut in drug
prices on the domestic front which impacts on their profits, pharmaceutical
firms in Japan are consolidating their operations through mergers:
Yamanouchi Pharmaceuticals Co. and Fujisawa Pharmaceuticals (April
2005), Sankyo Co. and Daiichi Pharmaceuticals (October 2005) and
Dainippon Pharmaceutical Co. and Sumitomo Pharmaceuticals (October
2005). These mergers have three goals: to improve their products in the
pipeline; to bolster their R&D and expand their sales force. But the real pur-
pose of these actions boils down to being able to compete with the well-
established firms in the West amid the stagnant domestic market, and to in-
crease their global competitiveness (Mayer, 2005).
In April 2005 Yamanouchi Pharmaceuticals Co., the fourth largest phar-
maceutical company in Japan and Fujisawa Pharmaceuticals, the fifth lar-
gest pharmaceutical company merged under a new name, Astellas Pharma
Inc. This symbiotic alliance will broaden their product offerings. Each of the
Astellas partner offers complementary products: Harnal, a urinary disorder
drug and Gaster, a peptic ulcer drug of.Yamanouchi Pharmaceuticals and
Prograf, a immunosuppressant sold by Fujisawa. To compete with the major
pharma companies worldwide, Astellas would build a global R&D through
better coordination of its R&D facilities and 1,200 scientists and researchers
in the US and Europe. Astellas's R&D costs for 2004 amounted to US&l.
2B. The senior officer of Astellas, Masao Shimizu said that the integrated
R&D which divides the work into basic research and development will allow
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mutual use of data on clinical tests as well as optimization of the global oper-
ations (Shimoda, 2005).
Sankyo Co. and Daiichi Pharmaceuticals, the second and sixth biggest drug
companies in Japan, respectively, integrated their operations in October
2005, making the merged company the second biggest pharmaceutical com-
pany in Japan. The changing business environment in the domestic market
as well as the stagnant growth of the two firms led to the consolidation of
their operations. The business integration of Sankyo Co. and Daiichi Phar-
maceutical Co. will bring together the drugs for the treatment of Alzheimers,
urology and infectious diseases which Daiichi is well-known for and
Sankyo's drugs for cardiovascular diseases (e.g. Mevalotin). This merger
will complement each alliance partner's strength not only in the manufactur-
ing but also in R&D. It will strengthen their global business presence be-
cause using both companies' sales forces abroad will maximize the scope of
their drugs for inflammation and immune disorder, arthritis, cardiovascular
and infectious diseases (Bioportfolio, 2005). The Sankyo-Daiichi merger
will have a pipeline of products such as Avandia for type 2 diabetes; Xolair
for allergic asthma, Memantine for Alzheimer; Plavis, a platelet anti-ag-
gregant that the new company can bank on for increased sales. The merger
hopes to spur R&D output portfolio as well as undergo pipeline consolidation
with a R&D budget of US$l.l B in 2004 (Mayer, 2005). The new Dainip-
pon Sumitomo Pharma Co. (merger of Dainippon Pharmaceutical Co, and
Sumitomo Pharmaceuticals Co.) will have a R&D budget of Y40-50B (U$
366-456 M). Patents of Dainippon on its anti-hypertension medication and
other drugs will expire in 2010 and will have negative effect on its revenues.
Hence the merger will consolidate production facilities and personnel as well
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streamline the products they will produce from 200 drugs to four drugs, con-
centrating in the manufacture and distribution of 2 drugs from each of the
merged companies, e.g., Gasmotin (Dainippon), a gastroprokinetic agent
and Amlodin (Sumitomo), a hypertension and angina pectoris drug. They
would like to focus their R&D on drugs for. diabetes and central nervous sys-
tem (Matsuzaki, 2005). As such, duplication of functions will be avoided in
this highly competitive and costly industry. The impressive performance of
Chugai. is manifested in its sales of Yen 315 B (US$2. 8B) and net profit of Y
51. 5 B (US$ 468M) in 2005. For the past decade, Chugai relied successfully
on two of its products: Epogin for renal anemia and Neutrogin, for blood dis-
order and Tamiflu for influenza (Hosaka, 2005) in spite of competition
from Kirin Brewery's Espo for Espogin and Kyowa Hakko Kogyo' s Neu-up
for Neutrogin. Its alliance partner, Roche which owns 51% of Chugai brings
several advantages: expand its product line and drugs in the pipeline, share
R&D costs, marketing tie-up and boost its international presence. Now the
company's product line includes anti-cancer agents and antiemetics, influen-
za treatment, etc.
Horizontal alliances in Biotech Industry: Biotechnology Across Borders
Learning by doing economics.suggests that the more the firm produces it
can exploit the benefits of the accumulated knowledge as it moves down the
experience curve resulting to more efficiency and cost reduction. There will
be more specialization and creation of dedicated assets and systems giving
the firm competitive advantage (Bartlett and Ghoshal, 1992). Hence, firms
specially small biotech firms who are at doldrums but want to develop global
scale medicines, can share and leverage on their unique strengths and
capabilities or core competences with other firms by forming horizontal alli-
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ances. Merlion Pharmaceutical Pte. Ltd is a small home-grown pharmaceuti-
cal company in Singapore which was a spin off from a public institution,
Centre for Natural Product Research (CNPR) a unit of Singapore's In-
stitute of Molecular Biology. The core assets of Merlion include the world's
largest and most diverse natural. product sample library.with potential phar-
maceutical applications not to mention the high throughput (HTP) screen-
ing of natural product samples to discover an array of new bioactive com-
pounds and natural product chemistry, skills for which reason many biotech
foreign companies would like to collaborate with Merlion. Banking on these
prime competences Merlion has formed strategic alliances with the following
big international biotech companies capitalizing on its collection of natural
compounds: (0 Sankyo (Japan) 2005: Discovery, clinical development and
commercialization of new therapeutic drugs from the natural product che-
mistry, Sankyo's expertise: Selected high throughput screens and addition-
al assays ( Biospace c, 2005); (i0 British Biotech (PIc) (UK) 2003: Discov-
ery and development of anti-bacterial ribosomal inhibitors from natural
sources, British Biotech's (PIc) expertise: Ribosomal biology and structure
based drug design, assays, crystallography and NMR technology (Merlion-
pharma b, 2003); Ciii)NovImmune S.A. (Switzerland) 2003: Discovery and
development of drugs for immunosuppression and immunomodulation using
natural products, NovImmune S.A.'s expertise: Identification, validation
and development of new therapeutic agents for inflammation, autoimmune
diseases, immunosuppression and immunomodulation (Merlionpharma c,
2003); Civ) Athelas (Switzerland) 2003: Discovery and pre-clinical research
of a new class of anti virus and anti infection drugs from natural product
samples, Athelas' expertise: Platform DiVi technology which can be used to
identify new target genes that lead to the appearance of virulence factors in
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many disease causing bacteria (Merlionpharma a, 2003); (v) Genome Ther-
apeutics (US) 2003: Discovery of anti infectives using natural occurring
compounds, Genome Therapeutics' expertise: Use Genomics to identify
genes essential for the growth of bacteria, fungi and other pathogens
(Biospace b, 2003); (vi)Abbott Laboratories (US) 2002: Drug discovery
for therapeutics in the fields of oncology,antivirus, immunology and nell'"
roscience using natural compounds, Abbott Laboratory's expertise: Capabil-
ity to identify potential therapeutic targets (Biospacea, 2003).
Way back in 1995, biomedicine technology has already been a mainstay
product of Japanese drug companies (e.g. rDNA insulin produced by Shiono-
gi, erythropoietin by Chugai, ·Kirin and Sankyo, human growth hormones by
Sumitomo and Yamanouchi and human growth hormones by Sumitomo
Chemicals and Yamanouchi). However, they relied more on the sale of
drugs licensed from multinational drug companies such as Pfizer, Novartis
and AstraZeneca. But ironically they would rather invest in foreign biotech
firms abroad to invigorate their dwindling pipeline of new drugs. Takeda
Pharmaceuticals through its venture capital subsidiary in the US, Takeda
Research Investment, has invested in biotech firms in the US and Lectus
Therapeutics in the UK. For another Kirin Brewery has invested in Merix
Bioscience of the US, to do jointly activities from research to commercializa-
tion of dendritic cell vaccines. With competition in the home market getting
severe with foreign multinationals' market share in the increase due to the
deregulation of the pharmaceutical market as well as their aggressive mar-
keting strategies Japanese companies are collaborating with Western
biotech companies. In 2003, Yamanouchi has inked an agreement with
Phytopharm, UK, and Takeda with Evotech, Germany for drug discovery
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alliance for Alzheimer. And in 2004, Mitsubishi Pharma signed deals with
Vertex Pharmaceuticals to develop and commercialize Oral HCV Protease
Inhibitor VX-950 for Hepatitis C in Japan and the Far East, and Takeda with
Andrx Corporation for Type 2 diabetes.
Outsourcing
In 1996, the global sales of recombinant pharmaceutical products were ap-
proximately US$607B. In India, the commercialization of nine recombinant
products-insulin (diabetes drug), alpha interferon (cancer drug), hepatitis
B vaccine, GMCSF,G-CSF, blood clotting factor 7, erythropoietin (drug
used in kidney failure), streptokinase (drug administered in heart attacks)
and human growth hormone have been approved. All these products except
Hepatitis-B are being imported at a cost of Rs 237 crores (US$53M). The
four major recombinant products with high market potentials in India are hu-
man insulin, alpha interferon, and erythropoietin (EPO). Domestic and for-
eign pharmaceutical companies are vying for the rising niche market for
recombinant DNA Erythropoietin (EPO) in India. With the prevalence of
kidney failure and anemia in India, there is a big market for EPOs in the
country estimated at Rs 75 crores (US$17M) in 2005, an increase of 25%
from the previous year. The first to develop EPO was Wockhardt in 2001 un-
der the brand name, EPOX. In 2005, after spending Rs20 crores (US$4. 4M)
Shanta Biotechnics launched its own version under the name, Shanpoietin.
Other competitors in the EPO market are: LG Life Sciences, India, Ranbax-
y, Johnson and Johnson, Emcure Pharamceuticals Zydus Cadila, and Hin-
dustan Antibiotics. All these pharmaceutical companies however have
licensed the manufacturing and marketing of EPOs to multinational drug
companies in India (Kulkarni, 2005). For example the government-owned
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drug manufacturer Hindustan's EPO, Hemax is outsourced to and marketed
in India by an American company, Elanex Pharmaceuticals. Since 5 years
ago, Emcure Pharmaceuticals of India has licensed out the marketing of its
EPO in the domestic market as well as in Southeast Asia to Dragon Phar-
maceuticals of the US. Since most of the r-EPOs sold in India are imported
they are rather expensive hence their usages are limited. To make the drug
more available to treat cancer and kidney ailments, Wockhardt is now sell-
ing it at a lower cost of Rs 798 (US$18) /2000iu/ml.·For its part, to compete
in the EPO market, Janssen-Cilag CRF, the Indian division of J&J success-
fully introduced, Eprex by stag in hospitals and scientific marketing. Other
domestic players are still interested in entering the EPO market such as In-
tas, Hindustan BioSciences Ltd (HBSL) as well as Kee Pharma Limited.
Cognizant of how expensive the EPOs are priced, HBSL will import them
from China's Shandong Kexing Bio Products Company Ltd. and sell them at
affordable prices.
Vertical Alliances in Biotechnology: Fast Access to Local and International
Markets
The reason behind the formation of across the border vertical alliances
among biotech specially biopharma firms is to secure fast and reliable access
to the global market or to previously closed markets utilizing the partners
distribution expertise and established network. LG Life Sciences of South
Korea develops and commercializes new anti-infection drugs, medicines for
cancer, diabetes, etc. Some of its well-known drugs are Euvax-B for the
treatment of Hepatitis B, LG HCD3. 0 for Hepatitis C and Factive
(Gemifloxacin), an antibiotic of the quinolone family which LG Life
Sciences jointly developed with GSK. In 2005, Sinovac Biotech Ltd. of
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China and LG Life Sciences of Korea have agreed on a sales and distribution
alliance. LG Science's known prowess is its knowledge of overseas market
development and its international marketing network. It already has well-
developed global sales and distribution networks for its HepB vaccine, in-
cluding UNICEF programs and distribution to 67 countries (Business Wire,
2005). Given this, LG Science will sell Sinovac's Hepatitis A vaccine (Hea-
live (tm)) and for its part of the deal Sinovac will introduce LG's HepB vac-
cines in the Chinese market. They will also work together on Sinovac's in-
fluenza vaccine (Anflu (tm) ). Sinovac and LG believe that there is tremen-
dous potential for selling LG's HepB vaccine in China hence LG will register
its HepB vaccine in China through Sinovac. Sinovac Biotech Ltd. specializes
in the research, development, commercialization, and sale of human vac-
cines for infectious illnesses such as hepatitis A and hepatitis B, influenza,
"SARS", and avian flu. The two vaccines of SINOVAC approved for com-
mercialization are: Healive (tm) for Hepatitis A and Bilive (tm) for Hepati-
tis A and B combined; both seen to have big market potentials in China.
SINOVAC is the global forerunner in the research and development of
SARS vaccine which is already awaiting approval. LG thus seeks to col-
laborate with SINOVAC in the development of the vaccine cognizant that it
is a novel drug with worldwide medical application.
Clinical Trials and Cost Advantage
Firms perform value creation in optimal locations to achieve location econo-
mies. Thus firms will locate in areas where there are relatively cheap and
high quality factor inputs to reduce the cost of value creation. One advantage
of Asia aside from the skilled manpower relates to cost. It costs around US$
800 M to develop a drug (CDSS 2002). The innovation and manufacturing
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costs as well as biotech services in India are less costly by international stan-
dards. For example, the price of Shanvac B, a hepatitis B vaccine produced
by a local company, Shantha Biotechnics costs only 50 cents/dose while the
imported vaccine costs US$16/dose. Biotech services are being outsourced
to biotech companies such as Syngene and SIRO Clinpharm in India which
can offer cheap and yet highly skilled labor force. Clinical test in the US
costs US$300-350 M whereas in India it will amount to only US$25M (San-
dhya, 2004). Costs in R&D in India for Streptokinase is US$ 1M whereas
in the US it is over US$20 M; clinical trials (Phase 1-111) for Rotavirus cost
US$ 5 M in India and over US$ 150 M in the US; development and produc-
tion of 3-Gmp tablets of new molecule-malaria cost US$l M in India and
more than US$ 20 M in the US (Bharat, 2004). Chinese scientists with doc-
toral degrees get a yearly salary of US$25 ,000, a mere 10 percent of what
scientists earn in the West. Hence complicated R&D such as biological test-
ing can be performed less expensively in China since salaries account for 80
% of total R&D costs. The savings then can be used to expand their pipeline
of potential blockbusters. "Doing research in a low-cost setting should allow
drug companies to deploy the dollars" they spend in the U.S. and Europe
more effectively, says Drew Senyei, a health-care venture capitalist at Enter-
prise Partners (Santini, 2004). The screening process of compounds with
medical application to novel drugs which has to be verified many times over
is very labor intensive. Roche has inaugurated an US$ 11 M laboratory in
Shanghai to screen different compounds that have potential use in anti-virus
and cancer drugs, to save on cost and to have access to the big Chinese mar-
ket. For labor intensive services and yet requiring high level skills, China
can offer low cost bioservices such as necleotide sequencing and synthesis,
protein expression and library construction (Chervenak, 2005). Multina-
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tional pharmaceutical companies conduct clinical tests in China where
recruitment of patients is not difficult and the related hospital fees are
cheaper. For these reasons, Germany's Mologen Inc. is having Starvax Inc.
of Beijing test the efficacy of a certain compound for a colon cancer drug
now undergoing clinical trials in Europe for the treatment of other forms of
cancer. WuXi Pharma Tech Co. (China) was approached by TargeGen, a
US pharmaceutical company that is developing small-molecule drugs for
cardiovascular ailments to perform chemical screening of various com-
pounds that can be used for further development (Santini, 2004).
Conclusion
The growth and development of the biotech sector in Asia have been quite u-
nique in a way. For one, government support and initiatives were imperative
for it to develop to where it is now. Many R&D were done in universities and
public laboratories the results of which could not be commercialized rapidly.
An efficient system to transfer technology to industry is not well in place and
venture capital was not as popular as in the West. Asians in general are risk
averse so they were hesitant to invest in risky bioventures. Hence the
government had to establish bioventure funds to compensate for the lack of
private venture capitalists. Since most of the researches have been done in
public institutions and laboratories, researches were focused on the treat-
ment of local/regional diseases due to immense political, social and econom-
ic implications of not doing so. Due to the globalization of pharmaceutical in-
dustry, firms have to rethink their strategies. For example pharmaceutical
companies are merging to rationalize their operations and product lines and
cut R&D costs. Some drug companies banking on their core competences
are forming strategic horizontal alliances with American and other Western
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biotech companies while others form cross border vertical alliances for clini-
cal trials and commercialization of the drugs. Having said this however,
biotech companies are now actively involved in new technology like genom-
ics and stem cell research. The advantage of Asia in this regard is its diverse
population which is vital to clinical testing and relatively cheap cost of doing
clinical trials. Other areas of biotechnology where Asia can have a niche is in
bioinformatics and nanotechnology. The recent increase in the number of
venture capitalists, bioventures and IPOs is a good indication that more peo-
ple now see that thebioeconomy can be a potential driver of economic
growth.
Asia is seen to be the next biotech hub for value creation activities such as
drug screening and drug manufacturing, bioinformatics and genomics.
Biotech companies in Asia are small in size and capitalization compared to
their Western counterparts and are still in the nascent stage. Amid the ever
increasing global competition pharmaceutical companies in the region are
strengthening their R&D activities to develop innovative drugs derived from
the biotech sector and pursuing global medicines for the maintenance of the
company rather than count on the manufacture of generics for most of their
revenues. To survive the competition and takeover from the more powerful
Western pharmaceutical companies and given the fact that after the costly
R&D only 15% of the drugs developed reach the commercialization stage
(CDSS, 2002), they form synergies using each partner's strengths and
share the R&D costs. Alliances can lead to increased market (international)
presence that will bring about economies of scale and scope. Biopharmaceu-
tical products and services have big market potentials in Asia specially for
novel drugs for the treatment of diseases common in the region such as
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respiratory and infectious disease and cardiovascular ailments which have
been the focus of many biotech firms in Asia, aside of course from the other
therapeutical medicines that have already been tested in the West for com-
mon ailments and licensed to drug companies in Asia. Moreover, Singapore,
South Korea and China hope to have an important niche in genomics and
stem cell research as well as their applications. Japan, India and South
Korea meanwhile can leverage on their strengths in IT and emerge as strong
in bioinformatics. Japan now puts its know-how in nanotechnology into prac-
tical use (nanomedicine) considered as the next generation drug delivery
system. Overall, local and international biotech and pharmaceutical firms
can bank on Asia in terms of market, location economies, economies of scale
and scope and innovation in genomics, stem cell research, bioinformatics and
nanomedicine in order to be competitive.
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